Zubair Shah, MD
Advanced Heart Failure and Transplant Cardiology · Kansas City, KSNPI 1386942126
Payments from drug & device makers
Across 1,266 payments — averaging $1828.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$2M
- AstraZeneca$106K
- Abbott$95K
- Ionis Pharmaceuticals, Inc.$38K
- Procyrion, Inc.$32K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29K
- plus $17K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 786 | $1,996,864 |
| AstraZeneca(2 entities) | 100 | $106,392 |
| Abbott | 84 | $95,255 |
| Ionis Pharmaceuticals, Inc. | 9 | $37,818 |
| Procyrion, Inc. | 2 | $32,392 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 101 | $29,254 |
| Pfizer | 52 | $6,439 |
| Akcea Therapeutics, Inc. | 5 | $3,896 |
| Bayer | 6 | $2,763 |
| Impulse Dynamics (USA) Inc. | 16 | $638 |
| Abiomed | 3 | $458 |
| Merck | 23 | $374 |
| Novo Nordisk | 19 | $372 |
| Novartis | 16 | $264 |
| Bridgebio Pharma, Inc. | 4 | $226 |
| Cvrx, Inc. | 1 | $151 |
| E.r. Squibb & Sons, L.L.C. | 6 | $120 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $112 |
| Paragonix Technologies, Inc. | 2 | $110 |
| Boston Scientific | 1 | $97 |
| Amgen | 5 | $85 |
| Edwards Lifesciences | 3 | $84 |
| Boehringer Ingelheim | 5 | $81 |
| Daxor Corporation | 1 | $69 |
| Ancora Heart, Inc. | 2 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
Too few advanced heart failure and transplant cardiology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Kansas City
- Hirak ShahKansas City$1.7M
- Paola RoldanKansas City$77K
- Pradeep MammenKansas City$18K
- Tarun DaliaKansas City$16K
- Michelle DimzaKansas City$12K
- Raja ZaghlolKansas City$5K
- Mohamed El KhashabKansas City$4K
- Jane TitteringtonKansas City$4K
- Daniel HarrisonKansas City$1K
- Deepthi VodnalaOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.